

Meeting Minutes
Incontinence in Neurological Disease - GDG Meeting 13
Location: National Clinical Guidelines Centre - Boardroom
9th December, 2011

GDG		NCGC	
Amelia Denny	AD	Gill Ritchie	GR
Clare Fowler	CF	Mark Perry	MP
Judith Jesky	JJ	Ralph Hughes	RH
Julie Vickerman	JV	Sharon Swain	SS
Paul Tophill	PT	Tamara Diaz	TD
Simon Harrison (Chair)	SH		
Keith MacDermott	KM	Observers	
Laura Graham	LGr	Clifford Middleton (NICE)	CM
Noreen Barker	NB	Michelle Wallwin (NICE)	MW
Apologies			
Alun Williams	AW		
Christine Anderson	CA		
Doreen Mc Clurg	DM		
Sue Woodward	SW		
Susie Orme	SO		

1. Welcome and Apologies

- 1.1. The Chair (SH) welcomed attendees to the Incontinence in Neurological Disease (IND) guideline development group (GDG) meeting 13 and apologies were heard for Alun Williams, Christine Anderson, Doreen Mc Clurg, Sue Woodward and Susie Orme.
- 1.2. The group was advised of meeting observers: Michelle Wallwin, the editor for this guideline and Clifford Middleton the guideline's commissioning manager, both from the National Institute for Clinical Excellence (NICE).

2. Declarations of Interest

- 2.1. The following declarations of interest were submitted to the group:
- 2.1.1. **SH:** Non-personal pecuniary interest: Joint organiser of spinal injury course. Catering expenses covered by Coloplast, American Medical Systems, Pfizer, Karl Sotrz Endoscopy, Amdipharm and Astellas.
- 2.1.2. **PT:** Non personal non-pecuniary interest: sponsorship of a teaching course he manages by Karl Storz Endoscopy, Pfizer, Amdipharm, American Medical Systems, Coloplast, Astellas Pharma
- 2.1.3. **CF:** Received money from TEVA for arranging a meeting on multiple system atrophy. Paid to attend an Allergan advisory board meeting. Attended advisory board on Biogen – payment to university. Royalties received from Allergan for speaking engagements.

3. Minutes of GDG 12

- 3.1. The Minutes of GDG 12 were reviewed and agreed by the GDG, pending the following changes:
- 3.2. Page 2, 6.1 – line 4 please put 'Botox' in brackets after, Botulinum Toxin Type A.

4. Matters arising from the Minutes of GDG 12

4.1. There were no outstanding matters arising from the notes and minutes of GDG 12.

5. The Chair presented an overview of the agenda.

6. Redrafting recommendations

The GDG reviewed recommendations for the questions listed below, with the assistance of the NICE editor.

- 6.1. Catheter valve safety
- 6.2. Urethral tape and sling surgery
- 6.3. Artificial urinary sphincter
- 6.4. Ileal conduit diversion
- 6.5. Prophylactic antibiotics
- 6.6. Configuration of services
- 6.7. Access to services
- 6.8. Provision of information

For consistency throughout the recommendations, the group agreed to use the word neurogenic instead of neuropathic except where it was grammatically incorrect.

7. Key Priorities for Implementation

The results of the recent voting exercise to select the top ten key priorities for the guideline were presented to the group. All present agreed on the list of recommendations which will form the key priority areas for the guideline.

8. Top 5 research recommendations

The GDG reviewed the results of the votes for the top 5 research recommendations and agreed on the final five.

9. Timelines and Key dates

Key Microprocess dates were highlighted for the group's attention.

10. Close of meeting

There being no further business the meeting ended at 12:55 p.m. The next meeting of the IND GDG will take place on 11th May, 2012 from 10:30 a.m. – 4:30 p.m. at the NCGC's offices located at 180 Great Portland Street, London, W1W 5QZ.